Compare Banco Bilbao Vizcaya Argentaria SA (BBVA) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Banco Bilbao Vizcaya Argentaria SA vs Mesoblast Limited — how do they compare? Banco Bilbao Vizcaya Argentaria SA trades at $25.57 (market cap $142.30B), while Mesoblast Limited trades at $18.21 (market cap $2.12B). The key difference: Banco Bilbao Vizcaya Argentaria SA is far larger — about 67.1× Mesoblast Limited's market cap, and Banco Bilbao Vizcaya Argentaria SA pays a 4.2% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| BBVA | MESO | |
|---|---|---|
Market Cap | $142.30B | $2.12B |
Sector | Financials | Technology |
52-Week High | $26.14 | $20.96 |
52-Week Low | $14.73 | $10.96 |
Dividend Yield | 4.2% | — |
Enterprise Value | — | $2.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BBVA trades at $25.39, down 1.17% on the day, with a bullish technical signal from moving averages and strong fundamental metrics including a 26.51% net income margin and 18.67% ROE. Recent earnings beat expectations in Q1 2026, and revenue has grown steadily from $28.2B in 2022 to $39.4B in 2025. Positive analyst sentiment is reflected in a 53.85% buy rating, though legal and regulatory risks from ongoing probes in Spain present headwinds.
The outlook for BBVA remains positive given robust profitability and analyst support, but investors should weigh the stock's attractive valuation against litigation risks and sector volatility. Upside potential exists if earnings continue to exceed forecasts, but legal developments could pressure the share price near-term.
MESO trades at $16.22, up 5.05% today, with a bullish technical outlook from moving averages but mixed oscillators. The company shows strong gross margins of 80.52% but remains unprofitable with a net income margin of -144.33%. Recent news highlights commercial progress, including Ryoncil revenue of $36 million in Q4 2026 and pivotal Phase 3 trial milestones for chronic low back pain.
The outlook is cautiously optimistic, driven by FDA-approved Ryoncil's revenue growth and pipeline advancements, but high valuation (P/S 30.52) and persistent losses pose risks. Analyst consensus leans buy (45.46%), yet investors face volatility from clinical trial outcomes and cash burn concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Banco Bilbao Vizcaya Argentaria SA
Despite its Spanish origins, BBVA generates three quarters of its profits in emerging markets, especially Mexico that contributes nearly half of BBVA's net profit. BBVA is overwhelmingly a retail and commercial bank with corporate and investment banking forming a smaller part of the overall business.
Read more on BBVA →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
